移植诊断公司CareDx（CDNA）今日盘前股价大跌6.26%，引发市场关注。该公司最新发布的财报业绩不及预期，同时还遭遇分析师下调目标价，这些因素共同导致了股价的大幅下挫。
根据公司公布的第二季度财报显示，CareDx实现调整后每股收益0.1美元，低于分析师预期的0.12美元；营收为8670万美元，同样未能达到市场预期的9060万美元。虽然公司第二季度调整后EBITDA为910万美元，高于预期的612万美元，但整体业绩表现仍不及预期，这可能是导致投资者信心受挫的主要原因之一。
另一方面，投行杰富瑞在最新的研究报告中将CareDx的目标价从25美元下调至21美元。分析师的悲观态度进一步加剧了市场对CareDx未来发展前景的担忧，这也是推动股价下跌的重要因素。
综上所述，CareDx盘前股价的大幅下跌主要受到公司财报不及预期以及分析师下调目标价的双重打击。投资者可能需要关注公司未来的业绩表现和市场反应，以评估CareDx的长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.